KUALA LUMPUR: Bintai Kinden Bhd's partner Generex Biotechnology Corporation has signed a US$50mil licensing and development deal for its Ii-Key vaccine platform technology.
It said on Thursday the agreement, which was signed with its partners in China, was for the technology provided by Generex’s subsidiary NuGenerex Immuno-Oncology Inc.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!